During the prodromal or mild cognitive impairment (MCI) phase, tau pathology emerges, and subtle cognitive deficits appear, with ongoing ApoE- and lipid-mediated effects on protein clearance, membrane composition, and synaptic function. This evidence concerns the gene MAPT and Cognitive impairment.